UNASSIGNED: This retrospective chart review presents preliminary data on a Human Performance Optimization (HPO) program that provided an average of 30 sessions of individualized alpha frequency repetitive transcranial magnetic stimulation (α-rTMS) to active-duty SOF as to reduce symptoms of PTSD and depression following traumatic brain injury. Scores from the PTSD Checklist for DSM-5, PROMIS Depression short form and Perceived Deficits Questionnaire (PDQ) were reviewed.
UNASSIGNED: Significant reductions were noted after the HPO program in all clinical scales with an average 37% decrease in PCL-5 (p<.01), 11.3% reduction in PROMIS depression T-scores (p<.01), and 45.5% reduction in PDQ scales by session 30 (p<.01), with side effects matching those commonly reported in rTMS. Importantly, the average PCL-5 score decreased from 42.9 to 27 by end of the treatment program, which is below the clinical threshold of 33 for presence of PTSD. For those with depression symptoms scores greater than cut off clinical thresholds at baseline, 46% resolved following treatment.
UNASSIGNED: This data provides preliminary support for safe application of α-rTMS for symptom reduction in active-duty special operations military personnel.
■此回顾性图表回顾提供了有关人类绩效优化(HPO)计划的初步数据,该计划平均为30次个性化的α频率重复经颅磁刺激(α-rTMS)提供了主动工作SOF,以减轻创伤性脑损伤后PTSD和抑郁症的症状。对DSM-5的PTSD清单,PROMIS抑郁简表和感知缺陷问卷(PDQ)的评分进行了综述。
■在所有临床规模的HPO计划后,PCL-5平均下降37%(p<.01),PROMIS抑郁T评分降低11.3%(p<0.01),到第30届会议时,PDQ量表减少45.5%(p<.01),副作用与rTMS中常见报道的副作用相匹配。重要的是,到治疗计划结束时,平均PCL-5评分从42.9降至27,低于PTSD存在的临床阈值33。对于抑郁症状评分高于基线临床阈值的患者,46%的人在治疗后解决。
■这些数据为安全应用α-rTMS以减轻现役特种作战军事人员的症状提供了初步支持。